Footnote: steroids do have a downside with CAR-T therapy also even though they can rescue a patient with CRS. We can forge a better CRS treatment alternative with Leronlimab.

“…use of higher cumulative dose of corticosteroids was associated with significantly shorter progression-free survival. More importantly, higher cumulative dose of corticosteroids, and prolonged and early use after CAR T-cell infusion were associated with significantly shorter overall survival. These results suggest that corticosteroids should be used at the lowest dose and for the shortest duration and their initiation should be delayed whenever clinically feasible while managing CAR T-cell therapy-associated toxicities.“

https://pubmed.ncbi.nlm.nih.gov/33534891/